Zobrazeno 1 - 10
of 81
pro vyhledávání: '"KIYOSHI OKAMOTO"'
Autor:
Osamu Tohyama, Junji Matsui, Kotaro Kodama, Naoko Hata-Sugi, Takayuki Kimura, Kiyoshi Okamoto, Yukinori Minoshima, Masao Iwata, Yasuhiro Funahashi
Publikováno v:
Journal of Thyroid Research, Vol 2014 (2014)
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1–
Externí odkaz:
https://doaj.org/article/ccb930de4714497d8a13ecd703c86a22
Autor:
Kohei Sawada, Norimasa Miyamoto, Masao Iwata, Kotaro Kodama, Yukinori Minoshima, Kazuma Takase, Megumi Ikemori Kawada, Kiyoshi Okamoto, Yusuke Narita
PDF - 86K, Cleavaged -PARP induction in A375 and G361 parental cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40fda413fcc7696489812e084a3521dc
https://doi.org/10.1158/1535-7163.22500801
https://doi.org/10.1158/1535-7163.22500801
Autor:
Kohei Sawada, Norimasa Miyamoto, Masao Iwata, Kotaro Kodama, Yukinori Minoshima, Kazuma Takase, Megumi Ikemori Kawada, Kiyoshi Okamoto, Yusuke Narita
PDF - 83K, Effect of vemurafenib, selumetinib, or E6201 on Cyclin D1 expression in exogenous MEK1-WT-positive or -negative A375 cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a474bc8cb4b1e9fe9f11006ed75633c0
https://doi.org/10.1158/1535-7163.22500810.v1
https://doi.org/10.1158/1535-7163.22500810.v1
Autor:
Kohei Sawada, Norimasa Miyamoto, Masao Iwata, Kotaro Kodama, Yukinori Minoshima, Kazuma Takase, Megumi Ikemori Kawada, Kiyoshi Okamoto, Yusuke Narita
PDF - 68K, Effect of vemurafenib, selumetinib, or E6201 on Cyclin D1 expression in (A) exogenous MEK1-C121S-positive or -negative G361 cells and in (B) exogenous MEK1-WT-positive or -negative G361 cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12305ed39ad8fa57e460db11a2b6c30d
https://doi.org/10.1158/1535-7163.22500804
https://doi.org/10.1158/1535-7163.22500804
Autor:
Kohei Sawada, Norimasa Miyamoto, Masao Iwata, Kotaro Kodama, Yukinori Minoshima, Kazuma Takase, Megumi Ikemori Kawada, Kiyoshi Okamoto, Yusuke Narita
PDF - 50K, Legends for Supplementary Figures 1 through 4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f6b4377c08e78c7fc45578cf968899a
https://doi.org/10.1158/1535-7163.22500798.v1
https://doi.org/10.1158/1535-7163.22500798.v1
Autor:
Akihiko Tsuruoka, Toshimitsu Uenaka, Masao Iwata, Junji Matsui, Tomohiro Matsushima, Toshimi Okada, Yoshinobu Yamane, Isao Ohashi, Yuki Karoji, Yusuke Nakatani, Yukinori Minoshima, Kiyoshi Okamoto, Naoko Hata Sugi, Satoshi Nagao, Setsuo Funasaka, Hiroko Kuramochi, Takayuki Nakagawa, Masaki Mikamoto, Yukiko Miyajima, Kotaro Kodama, Yuji Yamamoto, Saori Watanabe Miyano
IC50 values for the inhibition of 93 human kinases by E7090.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727d71c17112f88bd1dc928969d95751
https://doi.org/10.1158/1535-7163.22506370
https://doi.org/10.1158/1535-7163.22506370
Autor:
Akihiko Tsuruoka, Toshimitsu Uenaka, Masao Iwata, Junji Matsui, Tomohiro Matsushima, Toshimi Okada, Yoshinobu Yamane, Isao Ohashi, Yuki Karoji, Yusuke Nakatani, Yukinori Minoshima, Kiyoshi Okamoto, Naoko Hata Sugi, Satoshi Nagao, Setsuo Funasaka, Hiroko Kuramochi, Takayuki Nakagawa, Masaki Mikamoto, Yukiko Miyajima, Kotaro Kodama, Yuji Yamamoto, Saori Watanabe Miyano
Western blot analysis of FGFR1 in human lung cancer cell lines harboring FGFR1 amplifications.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f0cbd7b4c4157ac6029645427248557
https://doi.org/10.1158/1535-7163.22506373
https://doi.org/10.1158/1535-7163.22506373
Autor:
Kohei Sawada, Norimasa Miyamoto, Masao Iwata, Kotaro Kodama, Yukinori Minoshima, Kazuma Takase, Megumi Ikemori Kawada, Kiyoshi Okamoto, Yusuke Narita
Many clinical cases of acquired resistance to the BRAF inhibitor vemurafenib have recently been reported. One of the causes of this acquired resistance is the BRAF downstream kinase point mutation MEK1-C121S. This mutation confers resistance to not o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d10963634a99d6314e7ae3989d78d186
https://doi.org/10.1158/1535-7163.c.6536577.v1
https://doi.org/10.1158/1535-7163.c.6536577.v1
Autor:
Akihiko Tsuruoka, Toshimitsu Uenaka, Masao Iwata, Junji Matsui, Tomohiro Matsushima, Toshimi Okada, Yoshinobu Yamane, Isao Ohashi, Yuki Karoji, Yusuke Nakatani, Yukinori Minoshima, Kiyoshi Okamoto, Naoko Hata Sugi, Satoshi Nagao, Setsuo Funasaka, Hiroko Kuramochi, Takayuki Nakagawa, Masaki Mikamoto, Yukiko Miyajima, Kotaro Kodama, Yuji Yamamoto, Saori Watanabe Miyano
The FGFR signaling pathway has a crucial role in proliferation, survival, and migration of cancer cells, tumor angiogenesis, and drug resistance. FGFR genetic abnormalities, such as gene fusion, mutation, and amplification, have been implicated in se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99edbb82e8632667d9aa9e5d5b108ead
https://doi.org/10.1158/1535-7163.c.6538381.v1
https://doi.org/10.1158/1535-7163.c.6538381.v1
Autor:
Kohei Sawada, Norimasa Miyamoto, Masao Iwata, Kotaro Kodama, Yukinori Minoshima, Kazuma Takase, Megumi Ikemori Kawada, Kiyoshi Okamoto, Yusuke Narita
PDF - 164K, MAPK pathway inhibitory activity of the test compounds in G361.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b21214ed70527339d1143dfcb4e465b
https://doi.org/10.1158/1535-7163.22500807
https://doi.org/10.1158/1535-7163.22500807